Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Alexion Pharmaceuticals Inc patents


Recent patent applications related to Alexion Pharmaceuticals Inc. Alexion Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Alexion Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Alexion Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Alexion Pharmaceuticals Inc-related inventors


Methods of producing anti-c5a antibodies

The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to c5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, goodpasture's syndrome, and chronic obstructive pulmonary disease.. . ... Alexion Pharmaceuticals Inc

Methods of treating adamts13 deficiencies and congenital thrombotic thrombocytopenia in pediatric patients

Provided are methods for clinical treatment of an adamts 13 deficiency by administering an anti-c5 antibody, or antigen binding fragment thereof. Also, provided are methods for clinical treatment of congenital thrombotic thrombocytopenic purpura by administering an anti-c5 antibody, or antigen binding fragment thereof.. ... Alexion Pharmaceuticals Inc

Manufacturing of alkaline phosphatases

A method for producing a recombinant polypeptide, comprising: (a) providing a 100 l to 25,000 l fed-batch bioreactor comprising (i) cells capable of expressing the recombinant polypeptide asfotase alfa (seq id no: 1), and (ii) a culture medium suitable for conducting such expression the culture medium comprising about 25 μm to about 300 μm zinc; (b) culturing the cells under conditions suitable to express the recombinant asfotase alfa wherein the ph of the culture medium is about 6.7 to about 7.1, and wherein zinc is added into said culture medium such that the zinc concentration in the culture medium is maintained at a concentration of about 25 μm to about 300 μm of zinc.. . ... Alexion Pharmaceuticals Inc

Recombinant human ada2 and ada2 fusion proteins and methods for treating ada2 deficiencies

The present invention is directed to isolated recombinant human ada2 proteins, ada2 biologically active fragments, and ada2 fusion proteins. The proteins of the invention can be surprisingly used to restore ada2 activity in subjects having loss-of-function mutations in ada2 and increase differentiation of monocytes into macrophages, e.g., m2 macrophages, e.g., m2c macrophages, stimulate cd4+ t cell proliferation, and increase endothelial cell development. ... Alexion Pharmaceuticals Inc

Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof

The present invention provides pharmaceutical compositions comprising an a blood brain barrier peptide and a human peptide, such as an alpha-l-iduronidase (idua) protein, an iduronate-2-sulfatase protein (ids) protein, or an a galactosidase a protein (α-gal a) protein. The invention further provides methods of use for treating mucopolysaccharidosis type i (mps i), including hurler syndrome, hurler-scheie syndrome and scheie syndrome; methods of use for treating hunter syndrome; and methods of use for treating fabry disease.. ... Alexion Pharmaceuticals Inc

Methods of shifting an isoelectric profile of a protein product and uses thereof

Provided herein are methods shifting the isoelectric profile of a recombinant protein product and the use of such methods in the manufacture of recombinant protein products. Also provided are recombinant protein products produced by such methods.. ... Alexion Pharmaceuticals Inc

Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant

The present disclosure relates to, inter alia, a method of treating a patient in need of treatment with a c5 inhibitor or a method for inhibiting formation of terminal complement in a patient, comprising administering an effective amount of a c5 inhibitor, such as eculizumab or an eculizumab variant, to a patient who is or will be in compliance with vaccination with a neisseria meningococcal type b specific vaccine.. . ... Alexion Pharmaceuticals Inc

N-acetyl-alpha-d-glucosaminidase deficiency compositions and methods

Compositions and methods relating to potentially pathogenic mutations in the nucleotide sequence of a human naglu gene. Some naglu gene variants have been discovered to be associated with reduced n-acetyl-α-d-glucosaminidase (naglu) activity.. ... Alexion Pharmaceuticals Inc

A method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway

A method for measuring the protease activity of a convertase of the alternative complement pathway is provided. The method typically comprises immobilizing a biotinylated c3b on a solid phase coated with a biotin binding protein. ... Alexion Pharmaceuticals Inc

A method for measuring the protease activity of factor d of the alternative complement pathway

A method for measuring the protease activity of factor d for its natural substrate is provided. Factor d activity may be measured with an immunoassay or a biosensor. ... Alexion Pharmaceuticals Inc

Virus filtration

Provided herein are methods of performing viral filtration on a fluid including a recombinant antibody, and the use of these methods in methods of manufacturing or producing the recombinant antibody.. . ... Alexion Pharmaceuticals Inc

Producing therapeutic proteins

Facilities, methods, and systems to produce therapeutic protein(s) can include collecting eggs from transgenic avian in a production unit in a building; transferring the eggs to a harvesting unit in the building; and harvesting egg white or egg yolk from the eggs in the harvesting unit.. . ... Alexion Pharmaceuticals Inc

Anti-c5 antibodies having improved pharmacokinetics

The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the c5b-9 tcc) and c5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.. ... Alexion Pharmaceuticals Inc

Methods for treating complement-associated disorders

The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. ... Alexion Pharmaceuticals Inc

12/21/17 / #20170360899

Treating seizure with recombinant alkaline phosphatase

The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.. . ... Alexion Pharmaceuticals Inc

12/14/17 / #20170355759

Nebulization of monoclonal antibodies for treating pulmonary diseases

The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition.. . ... Alexion Pharmaceuticals Inc

12/07/17 / #20170349652

Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement

Eculizumab, a humanized monoclonal antibody against c5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (pnh). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global phase iii trial. ... Alexion Pharmaceuticals Inc

11/30/17 / #20170342139

Methods for treatment of refractory generalized myasthenia gravis

The disclosure provides methods of treating myasthenia gravis (mg) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (c5). In certain embodiments, the substance that specifically binds c5 is a binding protein, such as an anti-c5 antibody.. ... Alexion Pharmaceuticals Inc

10/05/17 / #20170285013

Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders

The disclosure relates to methods for detecting pnh type ii cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of pnh type ii cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.. ... Alexion Pharmaceuticals Inc

09/28/17 / #20170277835

Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor

This invention provides, inter alia, a complement-inhibitor-based treatment plan coupled with a risk evaluation and management strategy (“rems”) and a safety support program (“ssp”) for reinforcing the rems. The rems and spp are implemented using one or more computer devices with software tools programmed to enforce conditions of the rems and/or prompt follow-ups by registered nurses enrolled in the ssp. ... Alexion Pharmaceuticals Inc

09/21/17 / #20170269102

Atypical hemolytic uremic syndrome (ahus) biomarker proteins

The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (ahus) or clinically meaningful treatment of ahus with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. ... Alexion Pharmaceuticals Inc

09/21/17 / #20170267751

Prolongation of survival of an allograft by inhibiting complement activity

Methods of prolonging survival of allotransplanted cells, tissues or organs are presented. These methods are directed to administering to the allotransplant recipient an inhibitor of complement activity together with one or more immunosuppressants. ... Alexion Pharmaceuticals Inc

08/10/17 / #20170223938

Transgenic chickens with an inactivated endogenous gene locus

The present invention is transgenic chickens obtained from long-term cultures of avian pgcs and techniques to produce and transgenic birds derived from prolonged pgc cultures. In some embodiments, these pgcs can be transfected with genetic constructs to modify the dna of the pgc, specifically to introduce a transgene encoding an exogenous protein. ... Alexion Pharmaceuticals Inc

08/03/17 / #20170216413

Methods of treating mucopolysaccharidosis iiib (mpsiiib)

Methods for treating the central nervous system (cns) in a human patient with mucopolysaccharidosis (mps) mb who has an intact blood brain barrier, comprising intravenous administration of recombinant naglu.. . ... Alexion Pharmaceuticals Inc

08/03/17 / #20170216412

Recombinant human naglu protein and uses thereof

The present invention provides compositions comprising an isolated mixture of recombinant human naglu proteins in which a substantial amount of the naglu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of naglu proteins, vectors used in transgenesis and expression, host cells harboring such vectors, and methods of isolating and purifying the mixture of naglu proteins. ... Alexion Pharmaceuticals Inc

06/22/17 / #20170175094

Compositions and methods for treating craniosynostosis

Provided herein are compositions and methods for treating craniosynostosis. In particular, provided herein are methods of treating and preventing craniosynostosis by administering an isolated tnap polypeptide or a nucleic acid molecule that encodes a tnap polypeptide.. ... Alexion Pharmaceuticals Inc

06/01/17 / #20170151328

High concentration formulations of anti-c5 antibodies

The present disclosure relates to, inter alia, stable aqueous solutions comprising a high concentration of an antibody that binds to human complement component c5 and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders (for example, age-related macular degeneration or rheumatoid arthritis) using the solutions. ... Alexion Pharmaceuticals Inc

03/16/17 / #20170073399

Recombinant glycosylated eculizumab and eculizumab variants

The present disclosure relates to, inter alia, a recombinant eculizumab protein or a recombinant eculizumab variant protein having specific glycosylation patterns. The present disclosure relates to, inter alia, a recombinant eculizumab protein or a recombinant eculizumab variant protein made from cho cells. ... Alexion Pharmaceuticals Inc

01/26/17 / #20170023590

Atypical hemolytic uremic syndrome (ahus) biomarker proteins

The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (ahus) or clinically meaningful treatment of ahus with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. ... Alexion Pharmaceuticals Inc

01/19/17 / #20170015741

Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement

Eculizumab, a humanized monoclonal antibody against c5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (pnh). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global phase iii trial. ... Alexion Pharmaceuticals Inc

01/19/17 / #20170015740

Methods for treating complement-associated disorders

The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. ... Alexion Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Alexion Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Alexion Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###